- In May 2024, GE Healthcare unveiled its innovative Revolution RT, a state-of-the-art radiation therapy computed tomography (CT) solution. This cutting-edge technology aims to enhance imaging accuracy while optimizing simulation workflows. By improving precision in oncology care, Revolution RT is set to provide clinicians and patients with a more personalized treatment experience, thus positioning GE Healthcare favorably within the competitive medical imaging landscape
- In December 2020, Roche Holding AG received approval from the US FDA for its groundbreaking therapy, "Gavreto," aimed at treating patients with advanced mutant medullary thyroid cancer (MTC). This targeted therapy specifically addresses RET alterations, which play a crucial role in the development of medullary thyroid cancer. The approval not only expands treatment options for patients but also highlights Roche's commitment to advancing oncology therapeutics through innovative solutions
- In May 2020, Eli Lilly and Company achieved US FDA approval for Selpercatinib, a revolutionary drug designed for patients suffering from advanced RET-driven lung and thyroid cancer. This therapy specifically targets RET alterations, offering new hope to patients with these challenging conditions. By enhancing targeted treatment options, Selpercatinib reinforces Eli Lilly's position as a leader in the oncology space and addresses the urgent need for effective therapies
- In April 2020, Veracyte, Inc. launched the Afirma Xpression Atlas (XA) test, a groundbreaking diagnostic tool capable of detecting novel and rare gene alterations through advanced RNA sequencing. This innovative test is particularly promising in the field of thyroid cancer diagnostics, as it can significantly aid clinicians in making informed decisions regarding targeted therapies. The Afirma XA test is poised to improve patient outcomes by facilitating personalized treatment approaches
Frequently Asked Questions
The market is segmented based on Segmentation, By Product Type (Instruments, Consumables and Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Age Group (Below 21, 21-29, 30-65, and 65 and Above), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2031
.
The Global Thyroid Cancer Diagnostics Market size was valued at USD 7.50 USD Billion in 2023.
The Global Thyroid Cancer Diagnostics Market is projected to grow at a CAGR of 5.7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
